Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Return on Sales (2019 - 2025)

C4 Therapeutics' Return on Sales history spans 7 years, with the latest figure at 1.85% for Q4 2025.

  • For Q4 2025, Return on Sales rose 483.0% year-over-year to 1.85%; the TTM value through Dec 2025 reached 2.92%, up 4.0%, while the annual FY2025 figure was 2.92%, 4.0% up from the prior year.
  • Return on Sales reached 1.85% in Q4 2025 per CCCC's latest filing, up from 2.86% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.78% in Q4 2021 to a low of 13.48% in Q2 2023.
  • Average Return on Sales over 5 years is 5.0%, with a median of 3.27% recorded in 2021.
  • Peak YoY movement for Return on Sales: plummeted -1225bps in 2022, then skyrocketed 1201bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 0.78% in 2021, then plummeted by -1571bps to 13.03% in 2022, then rose by 18bps to 10.66% in 2023, then surged by 37bps to 6.68% in 2024, then skyrocketed by 72bps to 1.85% in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Return on Sales are 1.85% (Q4 2025), 2.86% (Q3 2025), and 4.03% (Q2 2025).